Drugs / OPC-1085EL
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02108288 | Apr → May 2014 | glaucoma, ocular hypertension | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05583474 | Sep 2022 → Nov 2024 | open-angle glaucoma | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02105285 | Apr 2014 → Jan 2015 | glaucoma, ocular hypertension | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02105272 | Apr 2014 → Mar 2015 | glaucoma, ocular hypertension | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPC-1085EL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02108288 ↗ |
| Route | Other | “OPC-1085EL ophthalmic solution” NCT02105272 ↗ |